Clinical Trial Update: Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating denosumab to preserve normal bone mineral density in women with breast cancer receiving adjuvant aromatase inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Kyoto Prefectural University of Medicine | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING